Levomilnacipran in the treatment of major depressive disorder : An analysis of efficacy and safety data from two phase III studies

被引：0
|
作者：
Greenberg, W. [1 ]
Commoll, C. [1 ]
Bose, A. [1 ]
Li, H. [1 ]
Ruth, A. [2 ]
Hussainzada, N. [3 ]
机构：
[1] Forest Res Inst, Jersey City, NJ USA
[2] Prescott Med, Commun Grp, Chicago, IL USA
[3] Forest Labs Inc, Washington, DC USA
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2012年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-14-014
引用
收藏
页码：184 / 184
页数：1
相关论文
共 50 条
  • [1] Levomilnacipran in the treatment of major depressive disorder: an analysis of efficacy and safety data from two phase III studies
    Greenberg, W.
    Gommoll, C.
    Bose, A.
    Li, H.
    Ruth, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S262 - S262
  • [2] The efficacy and safety of levomilnacipran in the treatment of major depressive disorder: Results from a phase III clinical trial
    Bose, A.
    Chen, C.
    Gommoll, C.
    Ruth, A.
    Hussainzada, N.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 182 - 182
  • [3] The efficacy and safety of levomilnacipran in the treatment of major depressive disorder: results from a phase III clinical trial
    Bose, A.
    Chen, C.
    Gommoll, C.
    Ruth, A.
    Terner-Rosenthal, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S261 - S262
  • [4] Levomilnacipran in the treatment of major depressive disorder: functional health and well-being efficacy results from a phase III trial
    Blum, S.
    Tourkodimitris, S.
    Ruth, A.
    Terner-Rosenthal, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S262 - S263
  • [5] LEVOMILNACIPRAN IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER: FUNCTIONAL HEALTH AND WELL-BEING EFFICACY RESULTS FROM A PHASE III CLINICAL TRIAL
    Blum, S., I
    Tourkodimitris, S.
    Ruth, A.
    VALUE IN HEALTH, 2012, 15 (04) : A91 - A91
  • [6] Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
    Huang, Qunlian
    Zhong, Xiaoyan
    Yun, Ye
    Yu, Bin
    Huang, Yilan
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2016, 12 : 2707 - 2714
  • [7] Levomilnacipran in the treatment of major depressive disorder: Functional health and well-being efficacy results from a phase III clinical trial
    Blum, S. I.
    Tourkodimitris, S.
    Ruth, A.
    Hussainzada, N.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 181 - 182
  • [8] Levomilnacipran for the treatment of major depressive disorder: a review
    Asnis, Gregory M.
    Henderson, Margaret A.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 125 - 135
  • [9] Effects of levomilnacipran er on measures of attention in a phase III trial of major depressive disorder
    Wesnes, K.
    Gommoll, C.
    Chen, C.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 142 - 142
  • [10] Effects of levomilnacipran ER on measures of attention in a phase III trial of major depressive disorder
    Wesnes, K.
    Gommoll, C.
    Chen, C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S383 - S383
12345